News - Bioniche Pharma
PITTSBURGH, Oct. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma received final approval from the U.S.
LAKE FOREST, Ill., July 28 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%. (Photo: http://photos.prnewswire.com/prnh/20100728/CG42156) (Photo: http://www.newscom.com/cgi-bin/prnh/20100728/CG42156) (Logo: http://photos.prnewswire.com/prnh/20080702/AQW070LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO) "Launching the first and only generic for Isosulfan Blue Injection 1% in the US reaffirms our commitment to introducing generic niche products, which allows hospitals and pharmacies an option in the buying process," said George Zorich, President, US Operations for Bioniche Pharma. Isosulfan Blue Injection 1% will be supplied in a carton containing six 5mL (10 mg/mL) single use vials. About Bioniche Pharma: Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche marke
LAKE FOREST, Ill., March 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags.